At the BNA Festival of Neuroscience, we had the pleasure of speaking with Barry Everitt about his talk on ‘Addiction: a compulsive interplay between drugs, cues and habits’.
Researchers have identified that the N-terminal fragment of galanin is involved in promoting anhedonia and could therefore be a potential therapeutic target for the treatment of depression.
Neuroimaging studies may help researchers understand how connections break down in different psychiatric conditions, which may improve our understanding of these disorders.
Researchers have demonstrated that cerebral organoids grown at the air–liquid interface are able to generate nerve tracts and stimulate muscle output; these could be used to improve understanding of neurological diseases such as dementia.
A team of neuroscientists has identified a group of cells in the hippocampus that can control fear memories. Understanding the mechanisms by which these cells activate and suppress memories could improve therapies for fear-based disorders.
A recent transnational study has determined that daily use of high potency cannabis can increase the risk of developing psychotic disorder.
For the first time in over 30 years, the US FDA has approved a new antidepressant called Spravato™ (esketamine) for treatment-resistant depression in adults.
Cannabis use amongst adolescents has been associated with increased risk of depression and anxiety in adulthood, according to a new study.
In the largest study of its kind, researchers have identified hundreds of genes newly linked to depression, shedding light on the origins of the condition.
Common somatic medications used to combat physical health diseases could bring significant benefits to people with mental illnesses.